Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lyophilised haemostat platelet derivatives - Cellphire

Next Previous
Drug Profile

Lyophilised haemostat platelet derivatives - Cellphire

Alternative Names: Freeze-dried platelets - Cellphire; Thrombosomes

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellphire
  • Class Blood products and substitutes; Cell therapies
  • Mechanism of Action Blood coagulation stimulants; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Thrombocytopenia

Most Recent Events

  • 21 Mar 2024 Cellphire completes an expanded-access programme for Thrombocytopenia in USA (IV, Infusion) (NCT04619108)
  • 22 May 2023 Cellphire Therapeutics terminates a phase II trial in Thrombocytopenia in USA, Norway and Israel (IV) due to loss of funding for the indication from the Biomedical Advanced Research and Development Authority (NCT04631211)
  • 16 Mar 2023 Phase-II clinical trials in Thrombocytopenia in Denmark (IV) (NCT05771831)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top